Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.

Front Pharmacol · 2025 · PMC12185402 · PMID 40556751

Europe PMC DOI

hedged sentence

0.6900

closest p · 13.8× alpha

0.6900

boldest claim

The sentences

did not reach statistical significancep = 0.69not close (p > 0.1)

Additionally, when the control group medication was abrocitinib, the variations between the dupilumab and abrocitinib groups did not reach statistical significance (p = 0.69). 3.6.2 Change in Hospital Anxiety depression scale (HADS) In the evaluation of the overall HADS score, a total of fifteen cohorts from six different studies were analyzed.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.